eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril

  title={eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril},
  author={P. S. Silva and Vanessa Fontana and Marcelo Rizzatti Luizon and Riccardo Lacchini and Welder A. Silva and Celso Biagi and Jos{\'e} Eduardo Tanus-Santos},
  journal={European Journal of Clinical Pharmacology},
PurposeThe antihypertensive effect of angiotensin-converting enzyme inhibitors (ACEi) is attributed partially to increased nitric oxide bioavailability. It is possible that functional polymorphisms in endothelial nitric oxide synthase (eNOS) and bradykinin receptor B2 (BDKRB2) genes may affect the antihypertensive response to enalapril.MethodsWe evaluated 106 hypertensive patients treated only with enalapril for 60 days. The difference between the mean arterial pressure (MAP) before and after… 

Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril

Findings suggest that polymorphisms in VEGFA gene may affect the antihypertensive responses to enalapril, a potent angiogenic factor that affects blood pressure by promoting vasodilation mediated by nitric oxide.

Gene–Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril

The results suggest that PRKCA polymorphisms and gene–gene interactions within the ACEi pathway affect the antihypertensive responses to enalapril.

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to EnAlapril in essential hypertension patients.

Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy

The pharmacogenetic impact of eNOS polymorphisms on the response to drugs affecting NO activity: angiotensin converting enzyme inhibitors, angiotENSin II receptor antagonists, calcium blockers, beta-blockers, diuretics, phosphodiesterase inhibitors, and statins are discussed.

Pharmacogenetic study of ACE, AGT, CYP11B1, CYP11B2 and eNOS gene variants in hypertensive patients from Faisalabad, Pakistan.

Inter-individual response to angiotensin converting enzyme inhibitor and angiotENSin receptor blocker was found to be independent of genetic polymorphisms in renin ang Elliotensin aldosterone system, endothelial nitric oxide synthase and 11-beta-hydroxylase genes.

Cross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertension

Substantial evidence is provided for the use of SNPs as predictors for enalapril response among South Africans adults with hypertension.

Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population.

Data suggest that AGTR1 and BDKRB2 are involved in ATV pharmacokinetics; a novel finding that requires confirmation in further studies.

Gene–gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

It is suggested that NAMPT polymorphisms affect plasma visfatin/NAMPT levels in nonresponsive PE patients, and that gene–gene interactions in the NAM PT pathway not only promote PE but also decrease the response to antihypertensive therapy in PE.

Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy.

It is suggested that eNOS haplotypes that have been associated with variable susceptibility to hypertension were not associated with LVH in hypertensive patients, even after adjustment in multiple linear regression analysis.



Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy

The results suggest that eNOS haplotypes are not associated with resistance to antihypertensive therapy and suggest a protective effect for the ‘C Glu b’ haplotype against hypertension.

eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity

Findings suggest that a short treatment with atorvastatin is disadvantageous to subjects with the CC genotype for the T-786C polymorphism compared to those with TT genotype, at least in terms of the hemorheological properties of erythrocytes.

Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction

Evidence is shown that eNOS polymorphisms affect the responses of PED and clinical ED patients to sildenafil, and these polymorphisms were more common in GR than in PR patients with clinical ED.

eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension

Variations of the endothelial nitric oxide synthase (eNOS) gene have been associated with hypertensive disorders of pregnancy and the ‘C-Glu-a' and ‘T-Asp-a’ hapotypes were associated with responsiveness and nonresponsiveness to therapy, thus suggesting that eNOS haplotypes affect the responsiveness to antihypertensive therapy in PE.

Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers

The data show that enalapril 10–20 mg/day does not affect the concentrations of relevant markers of NO formation or markers of oxidative stress in mild to moderately hypertensive subjects, despite satisfactory blood pressure control.

The T-786→C Mutation in Endothelial Nitric Oxide Synthase Is Associated With Hypertension

The interaction between the endothelial NO synthase T-786→C polymorphism and blood pressure in a large clinically healthy population was investigated and it was found that subjects with the C/C genotype had significantly higher systolic blood pressures and were 2.3 to 3.7 more likely to be hypertensive.